A goal for developers of immunomodulatory drugs has long been a systemically administered small molecule that can selectively inhibit inflammation in specific tissues. The chemokine receptor CCR9 is an attractive target for this approach, as entry of T cells into the small intestine from blood requires interaction between CCR9 and its ligand CCL25. We have tested the ability of a small molecule CCR9 antagonist, CCX8037, to inhibit antigen-mediated T cell accumulation in the intestine. This compound prevented accumulation of gut-imprinted antigen-specific CD8 T cells within epithelium of the small intestine. Interestingly, the antagonist did not affect the robust generation of gut-imprinted CD8 T cells within mesenteric lymph nodes. To distinguish “gut-selective” from “general” T cell inhibition, we tested the drug’s ability to influence accumulation of T cells within skin, a tissue in which CCR9 plays no known role, and we found no appreciable effect. This study demonstrates the feasibility of creating systemically-administered pharmaceuticals capable of tissue-selective immune modulation. This proof of concept is of utmost importance for designing effective treatments against various autoimmune disorders localized to a specific tissue.
References
[1]
Campbell JJ, Butcher EC (2000) Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr. Opin. Immunol. 12: 336–341.
[2]
Butcher EC, Williams M, Youngman K, Rott L, Briskin M (1999) Lymphocyte trafficking and regional immunity. Adv. Immunol. 72: 209–253.
[3]
Villablanca EJ, Cassani B, von Andrian UH, Mora JR (2011) Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 140: 1776–1784.
[4]
Zollner TM, Asadullah K, Schon MP (2007) Targeting leukocyte trafficking to inflamed skin: still an attractive therapeutic approach? Exp. Dermatol. 16: 1–12.
[5]
Baekkevold ES, Wurbel MA, Kivisakk P, Wain CM, Power CA, et al. (2005) A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations. J. Exp. Med. 201: 1045–1051.
[6]
Campbell JJ, O’Connell DJ, Wurbel MA (2007) Cutting Edge: Chemokine receptor CCR4 is necessary for antigen-driven cutaneous accumulation of CD4 T cells under physiological conditions. J Immunol. 178: 3358–3362.
[7]
Tubo NJ, McLachlan JB, Campbell JJ (2011) Chemokine receptor requirements for epidermal T-cell trafficking. Am. J. of Pathol. 178: 2496–2503.
[8]
Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC (2001) CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med. 194: 1541–1547.
[9]
Eksteen B, Adams DH (2010) GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn’s disease. IDrugs 13: 472–781.
[10]
Keshav S, Johnson D, Bekker P, Schall TJ (2009) PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn’s Disease. Gastroenterology 136: A65–A65.
[11]
Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, et al. (2010) Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 335: 61–69.
[12]
Wurbel MA, Malissen M, Guy-Grand D, Malissen B, Campbell JJ (2007) Impaired accumulation of antigen-specific CD8 lymphocytes in chemokine CCL25-deficient intestinal epithelium and lamina propria. J. Immunol. 178: 7598–7606.
[13]
Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, et al. (1994) T cell receptor antagonist peptides induce positive selection. Cell 76: 17–27.
[14]
Sigmundsdottir H, Butcher EC (2008) Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat. Immunol. 9: 981–987.
